In This Article:
The United States market has shown a positive trend, climbing 1.6% in the last week and rising 12% over the past year, with earnings projected to grow by 14% annually. In this environment, identifying stocks that are potentially undervalued can offer investors opportunities to capitalize on future growth while benefiting from current market conditions.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Quaker Chemical (NYSE:KWR) | $105.85 | $210.37 | 49.7% |
| KBR (NYSE:KBR) | $55.45 | $108.68 | 49% |
| Horizon Bancorp (NasdaqGS:HBNC) | $15.69 | $30.69 | 48.9% |
| Flowco Holdings (NYSE:FLOC) | $19.17 | $37.91 | 49.4% |
| Curbline Properties (NYSE:CURB) | $23.62 | $47.17 | 49.9% |
| Constellation Brands (NYSE:STZ) | $192.91 | $385.37 | 49.9% |
| Array Technologies (NasdaqGM:ARRY) | $7.265 | $14.21 | 48.9% |
| FinWise Bancorp (NasdaqGM:FINW) | $14.85 | $29.22 | 49.2% |
| TransMedics Group (NasdaqGM:TMDX) | $122.10 | $238.94 | 48.9% |
| Mobileye Global (NasdaqGS:MBLY) | $15.72 | $31.08 | 49.4% |
Here we highlight a subset of our preferred stocks from the screener.
Grab Holdings
Overview: Grab Holdings Limited operates as a superapp provider in Southeast Asia, offering a range of services including transportation, food delivery, and digital payments across countries such as Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam; it has a market cap of approximately $20.72 billion.
Operations: The company's revenue segments include Mobility at $1.08 billion, Deliveries at $1.56 billion, and Financial Services at $273 million.
Estimated Discount To Fair Value: 37.5%
Grab Holdings is trading at US$5.08, below its estimated fair value of US$8.13, presenting a potential undervaluation based on cash flows. The company recently reported a net income of US$10 million for Q1 2025, turning profitable from a previous net loss. While expected revenue growth is moderate at 14.1% annually, earnings are forecasted to grow significantly at over 40% per year, suggesting strong future cash flow potential despite low return on equity forecasts.
-
The growth report we've compiled suggests that Grab Holdings' future prospects could be on the up.
-
Dive into the specifics of Grab Holdings here with our thorough financial health report.
Sarepta Therapeutics
Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of approximately $3.58 billion.
Operations: The company's revenue primarily comes from its activities in discovering, developing, manufacturing, and delivering therapies, totaling $2.23 billion.